NEW YORK, May 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=146598&from=4CLASS PERIOD: March 1 ...

Group 1: Bond Issuance - The company has successfully placed CHF-denominated unsecured bonds totaling approximately CHF 3.5 million, subscribed by investors in Switzerland and Liechtenstein [2] - The settlement of the bond issue is expected to occur on 5 May 2025, and the bonds will not be listed on any stock exchange or trading venue [2] - The bonds have a term of three years, maturing on 30 April 2028, with an interest rate of 10% per annum and quarterly interest payments starting on 30 September 2025 [3] Group 2: Corporate Purpose and Financial Details - The net proceeds from the bond issuance will be used for general corporate purposes [2] - The bonds are callable at par value at quarterly intervals, with the first call option available on 30 June 2026 [3] Group 3: Company Overview - Hofseth BioCare ASA is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [3] - The company upcycles side streams of the salmon industry into health-improving ingredients such as ProGo®, OmeGo®, and CalGo® / NT-II((TM)) [3][4] - Hofseth BioCare emphasizes scientific evidence and has established academic partnerships to identify unique health benefits, including improved iron metabolism and immune health [4] Group 4: Research and Development - The company has received patents for its discoveries and has spun out a biotech-focused company, HBC Immunology, which is developing therapeutics for prostate and ovarian cancer, as well as a therapy for asthma [4]

Core Insights - NurExone Biologic Inc. is enhancing its engagement with the European financial and healthcare sectors by participating in three significant events, following the announcement of a potential third therapeutic indication for its lead drug asset, ExoPTEN [1][5] Group 1: Upcoming Events and Participation - CEO Dr. Lior Shaltiel will represent NurExone at INVEST 2025 in Stuttgart, a key investment conference for German-speaking markets, where the company will present its corporate strategy and pipeline development [2][3] - NurExone is also participating in the Healthtech Roadshow in Zurich from May 5-8, 2025, aimed at engaging healthcare professionals and life science investors in Switzerland [3] - From May 12-15, 2025, Dr. Shaltiel will present at BioProcess International Europe in Hamburg, discussing the company's exosome-based siRNA therapy and its ExoTherapy platform [4] Group 2: Strategic Goals and Growth Narrative - The participation in these events is designed to increase visibility for NurExone's innovative approach to regenerative medicine, particularly with the identification of a third potential indication for ExoPTEN, which enhances the company's growth narrative [5] - NurExone plans to maintain an active presence at key European conferences throughout 2025 to strengthen investor relations and foster strategic collaborations in the healthcare and biotech sectors [6] Group 3: Company Overview and Product Focus - NurExone Biologic Inc. is focused on developing exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing promising preclinical data for treating spinal cord and optic nerve injuries, both of which are multi-billion-dollar markets [7] - The company has received Orphan Drug Designation, facilitating its roadmap towards clinical trials in the U.S. and Europe, and has established Exo-Top Inc. as a U.S. subsidiary to support its North American growth strategy [7]

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zl ...

Core Viewpoint - Legend Biotech Corporation has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2][3]. - The recent upgrade for Legend Biotech suggests an improvement in its earnings outlook, which could lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimates on Stock Prices - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, influenced by institutional investors [5]. - Rising earnings estimates and the corresponding rating upgrade for Legend Biotech imply a positive trend in the company's underlying business, which should be reflected in its stock performance [6]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [8]. - The upgrade of Legend Biotech to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11]. Earnings Estimate Revisions for Legend Biotech - For the fiscal year ending December 2025, Legend Biotech is expected to earn -$0.64 per share, reflecting a year-over-year change of -23.1% [9]. - Over the past three months, the Zacks Consensus Estimate for Legend Biotech has increased by 8.9%, indicating a positive revision trend [9].

Clermont-Ferrand (France), May 2, 2025 (6:00 pm CEST). CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces to its shareholders and the financial community that its 2024 Universal Registration Document including the annual report, the management report and the report on corporate governance was filed with the French Financial Market Authority (Autorité des marchés financiers) on Ap ...

Core Viewpoint - Legend Biotech Corporation (LEGN) shows significant upside potential with a mean price target of $79.86, indicating a 135.2% increase from its current price of $33.96 [1] Price Targets - The average of 19 short-term price targets ranges from a low of $55 to a high of $95, with a standard deviation of $11.93, suggesting a variability in estimates [2] - The lowest estimate indicates a 62% increase, while the most optimistic estimate points to a 179.7% upside [2] Analyst Consensus - Analysts have shown strong agreement in revising earnings estimates higher, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 15.5%, with three estimates moving higher and no negative revisions [12] Zacks Rank - LEGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Financial Data and Key Metrics Changes - The proposal for a reverse stock split has been approved by a majority of votes, indicating a strategic move to potentially enhance the stock price and attract more investors [6] - The adjournment proposal was also approved, allowing for further solicitation of proxies if necessary [6] Business Line Data and Key Metrics Changes - No specific financial data or performance metrics for individual business lines were provided during the meeting [7] Market Data and Key Metrics Changes - There was no detailed market data or key metrics discussed in the meeting [7] Company Strategy and Development Direction - The company is focused on clinical trials and is committed to reporting data as it becomes available, emphasizing transparency in their research process [8] - The management is preparing to draw down NIH grant funding in the foreseeable future, indicating ongoing reliance on external funding sources [9] Management Comments on Operating Environment and Future Outlook - Management has not experienced adverse effects from NIH grant funding cuts to date, but they are cautious about future implications [9] - The company is optimistic about the nature of their grant and the timing, although uncertainties remain [9] Other Important Information - The meeting concluded with a commitment to report clinical trial data as expeditiously as possible, highlighting the importance of quality control and safety review processes [8] Q&A Session Summary Question: How often are clinical trial assessments done during the current clinical study? - Management stated that they report data as soon as it is available, emphasizing the need for quality control and committee checks before publishing results [8] Question: Has your NIH grant funding been affected by the recent funding cuts? - Management confirmed that there have been no adverse effects from NIH grant funding so far, but they are preparing to draw down funds soon, with future implications still uncertain [9]

Core Viewpoint - Longeveron Inc. is set to report its first quarter 2025 financial results and provide a business update on May 8, 2025, after U.S. market close, followed by a conference call and webcast [1] Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to meet unmet medical needs [3] - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [3] - Laromestrocel has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [3] Pipeline and FDA Designations - Longeveron is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease (AD), and aging-related frailty [3] - The HLHS program has received three FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [3] - The AD program has received two important FDA designations: Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [3]

Company Overview - ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment and improving patient survival [2] - The company's lead candidate, evorpacept, is positioned as a potential cornerstone therapy in immuno-oncology and is currently undergoing multiple clinical trials across various cancer indications [2] - ALX Oncology's second candidate, ALX2004, is an innovative EGFR-targeted antibody-drug conjugate expected to enter Phase 1 trials in mid-2025 [2] Financial Reporting - ALX Oncology plans to report its first quarter 2025 financial results on May 8, 2025, before the market opens [1] - The company will not hold a teleconference in conjunction with the financial results press release [1]